May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Paradoxical Intraocular Pressure (IOP) Rise With Titanium Sapphire Selective Laser Trabeculoplasty (TiSaLT)
Author Affiliations & Notes
  • L. Ogunbowale
    Glaucoma Research Unit, Moorfields Eye Hospital, London, United Kingdom
  • A. Spratt
    Glaucoma Research Unit, Moorfields Eye Hospital, London, United Kingdom
  • N. Anand
    Calderdale and Huddersfield NHS Trust, Yorkshire, United Kingdom
  • W. Franks
    Glaucoma Research Unit, Moorfields Eye Hospital, London, United Kingdom
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 3974. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. Ogunbowale, A. Spratt, N. Anand, W. Franks; Paradoxical Intraocular Pressure (IOP) Rise With Titanium Sapphire Selective Laser Trabeculoplasty (TiSaLT). Invest. Ophthalmol. Vis. Sci. 2007;48(13):3974.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose:: Nd:YAG Selective laser trabeculoplasty (SLT) has been reported to reduce IOP. To report the treatment results of patients receiving TiSaLT.

Methods:: We used TiSaLT at 780nm wavelength to treat raised IOP in eyes with ocular hypertension (OHT), primary open angle glaucoma (POAG), glaucoma complicating pigment dispersion syndrome (PDS) and pseudoexfoliation (PXE) inadequately controlled with, or intolerant of, medical treatment.

Results:: Two UK centers treated 67 eyes of 44 patients. Twenty five were women, mean age [range] was 64 [27-85] years. Seven eyes had PDS, three PXE, nine OHT and 48 POAG. Mean follow-up was 42 [4-91] weeks. Mean number of pre-treatment medicines was 2.1 and post-treatment 1.8 (t-test: p=0.043). Mean pre-treatment IOP was 23.1mmHg [15-34] and final post-treatment IOP was 20.0mmHg [5-40]. Nineteen eyes had an immediate IOP fall, five achieving a satisfactory target pressure. Forty eight eyes had an IOP rise within four weeks of treatment: 1-5mmHg in 21 eyes, 6-10 mmHg in 16 eyes, 11-20mmHg in 5 eyes and >21 mmHg in 6 eyes. This initial IOP rise settled in 21 eyes without additional medication. Five eyes had repeat TiSaLT without success; 12 eyes needed trabeculectomy surgery within 60 weeks of treatment (mean 36 weeks [4-60]). IOP of the 10 eyes with PDS and PXE rose by a mean of 7mmHg [-9 to +19].

Conclusions:: The IOP outcomes of TiSaLT were inferior to those of frequency-doubled Nd:YAG SLT. TiSaLT was also associated with a significant risk of acute IOPrise.

Clinical Trial:: European Community Trials Database

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • laser • intraocular pressure 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×